USD
+$0.00
(+0.00%
)At Close (As of Oct 13, 2025)
$125.59M
Market Cap
-
P/E Ratio
-0.43
EPS
$2.59
52 Week High
$0.49
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | - |
Total Revenue | $0 |
Cost Of Revenue | - |
Costof Goods And Services Sold | - |
Operating Income | -$30M |
Selling General And Administrative | $7.2M |
Research And Development | $23M |
Operating Expenses | $30M |
Investment Income Net | - |
Net Interest Income | $3.2M |
Interest Income | $3.2M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $53K |
Income Before Tax | -$27M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$27M |
Comprehensive Income Net Of Tax | - |
Ebit | -$27M |
Ebitda | -$27M |
Net Income | -$27M |
Field | Value (USD) |
---|---|
Total Assets | $98M |
Total Current Assets | $98M |
Cash And Cash Equivalents At Carrying Value | $94M |
Cash And Short Term Investments | $94M |
Inventory | - |
Current Net Receivables | - |
Total Non Current Assets | $231K |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | - |
Other Current Assets | $3.5M |
Other Non Current Assets | - |
Total Liabilities | $2.9M |
Total Current Liabilities | $2.7M |
Current Accounts Payable | $1.5M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $107K |
Total Non Current Liabilities | $112K |
Capital Lease Obligations | $219K |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $219K |
Other Current Liabilities | $1.2M |
Other Non Current Liabilities | - |
Total Shareholder Equity | $95M |
Treasury Stock | - |
Retained Earnings | -$95M |
Common Stock | $90K |
Common Stock Shares Outstanding | $58M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$15M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $11K |
Capital Expenditures | $15M |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | -$15M |
Cashflow From Financing | $109M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$27M |
Field | Value (USD) |
---|---|
Gross Profit | - |
Total Revenue | $0 |
Cost Of Revenue | - |
Costof Goods And Services Sold | - |
Operating Income | -$30M |
Selling General And Administrative | $7.2M |
Research And Development | $23M |
Operating Expenses | $30M |
Investment Income Net | - |
Net Interest Income | $3.2M |
Interest Income | $3.2M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $53K |
Income Before Tax | -$27M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$27M |
Comprehensive Income Net Of Tax | - |
Ebit | -$27M |
Ebitda | -$27M |
Net Income | -$27M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Context Therapeutics Inc. is a late-stage biopharmaceutical company based in Boston, Massachusetts, dedicated to discovering and commercializing innovative, non-opioid therapies for chronic pain management. With a strong pipeline of therapies aimed at addressing significant unmet medical needs, Context Therapeutics is positioned to impact the treatment landscape significantly. The company's commitment to developing non-addictive solutions underscores its mission to enhance patient outcomes while reducing reliance on opioids.